L'Oreal flags GLP-1 impact on beauty sales, signals consumer shift

L'Oreal's CEO publicly acknowledged that GLP-1 weight-loss drug use is affecting beauty and skincare sales, marking a notable corporate admission of a demand shift. The comment suggests a structural change in consumer behavior tied to weight-loss treatments, with implications for the beauty sector's growth outlook. The extent of the impact across product categories remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works